![]() |
產(chǎn)地 | 進口、國產(chǎn) |
品牌 | 上海莼試 |
保存條件 | Store at -20 °C |
貨號 | CS12127 |
應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
CAS編號 | |
抗體名 | Anti-SOX9/SRA1 |
克隆性 | 是 |
靶點 | 詳見說明書 |
適應(yīng)物種 | 詳見說明書 |
形態(tài) | 詳見說明書 |
宿主 | 詳見說明書 |
亞型 | IgG |
標識物 | 詳見說明書 |
濃度 | 1mg/1ml% |
免疫原 | KLH conjugated synthetic peptide derived from human SOX9 |
產(chǎn)品訂購信息:
英文名稱 Anti-SOX9/SRA1
中文名稱 轉(zhuǎn)錄因子SOX9蛋白抗體品牌
別 名 CMD 1; CMD1; CMPD 1; CMPD1; SOX 9; Sox9; SOX9_HUMAN; SRA 1; SRA1 antibody SRY (sex determining region Y) box 9 (campomelic dysplasia autosomal; SRY (sex determining region Y) box 9; SRY (sex determining region Y)-box 9; SRY (sex-determining region Y)-box 9 protein; Transcription factor SOX 9; Transcription factor SOX-9; transcription factor SOX9; campomelic dysplasia autosomal sex reversal.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Rabbit
產(chǎn)品類型 一抗
研究領(lǐng)域 細胞生物 免疫學 發(fā)育生物學 染色質(zhì)和核信號 神經(jīng)生物學 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學
蛋白分子量 predicted molecular weight: 56kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SOX9
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
轉(zhuǎn)錄因子SOX9蛋白抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 The protein encoded by this gene recognizes the sequence CCTTGAG along with other members of the HMG-box class DNA-binding proteins. It acts during chondrocyte differentiation and, with steroidogenic factor 1, regulates transcription of the anti-Muellerian hormone (AMH) gene. Deficiencies lead to the skeletal malformation syndrome campomelic dysplasia, frequently with sex reversal. [provided by RefSeq].
Function : Plays an important role in the normal skeletal development. May regulate the expression of other genes involved in chondrogenesis by acting as a transcription factor for these genes.
Subcellular Location : Nucleus (Potential).
DISEASE : Defects in SOX9 are the cause of campomelic dysplasia (CMD1) [MIM:114290]. CMD1 is a rare, often lethal, dominantly inherited, congenital osteochondrodysplasia, associated with male-to-female autosomal sex reversal in two-thirds of the affected karyotypic males. A disease of the newborn characterized by congenital bowing and angulation of long bones, unusually small scapulae, deformed pelvis and spine and a missing pair of ribs. Craniofacial defects such as cleft palate, micrognatia, flat face and hypertelorism are common. Various defects of the ear are often evident, affecting the cochlea, malleus incus, stapes and tympanum. Most patients die soon after birth due to respiratory distress which has been attributed to hypoplasia of the tracheobronchial cartilage and small thoracic cage.
Defects in SOX9 are the cause of 46,XX sex reversal type 2 (SRXX2) [MIM:278850]. SRXX2 is a condition in which male gonads develop in a genetic female (female to male sex reversal).
Similarity : Contains 1 HMG box DNA-binding domain.
Database links : UniProtKB/Swiss-Prot: P48436.1
Sox9是軟骨形成過程中一個十分關(guān)鍵的轉(zhuǎn)錄因子,已經(jīng)有研究表明骨形成蛋白2(bone morphogenetic protein 2,BMP2)能誘導Sox9的表達。
有學者認為;Sox9蛋白很可能與椎間盤退變有著密切的關(guān)系,Sox9是膠原蛋白合成過程中的一個重要的轉(zhuǎn)錄因子,且在軟骨的發(fā)育、成熟過程中對膠原蛋白有著正向調(diào)控作用,Sox9蛋白在男性性腺。
G蛋白信號轉(zhuǎn)導調(diào)控蛋白4 多克隆抗體 RGS4 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
血型多肽RHCE 多克隆抗體 RHCE Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
RhoGTP酶激活蛋白4 多克隆抗體 RHG04 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
RhoGTP酶激活蛋白5 多克隆抗體 RHG05 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
RhoGTP酶激活蛋白6 多克隆抗體 RHG06 Polyclonal Antibody 700/30ul#1540/100ul#2520/200ul
三磷酸腺苷結(jié)合轉(zhuǎn)運蛋白G超家族成員2抗體 組織相容性復合體蛋白1抗體
性癥突變蛋白抗體 組織相容性復合體β抗體
氨肽酶A抗體 組織相容性復合體α抗體
ATP結(jié)合蛋白家族7抗體 組織相容性復合體2抗體
ASCL2蛋白抗體 組織相關(guān)抗原HLA-B15抗體
組織因子途徑抑制劑抗體 9號染色體開放閱讀框163抗體
瞬時受體電位通道1抗體 9號染色體開放閱讀框156抗體
酪氨酸酶相關(guān)蛋白1抗體 9號染色體開放閱讀框153抗體
血小板生成素/巨核細胞集落刺激因子抗體 9號染色體開放閱讀框152抗體
內(nèi)皮標志物8抗體 9號染色體開放閱讀框150抗體
瓜馥木Fissistigma oldhamii Piperolactam C none 116064-76-7 C18H15NO4 ≥95%
白綿馬速AAWhitqcspidinccHPLC≥98%;20mg/支
安格洛苷C 安格洛甙 C Angoroside C 115909-22-3 ≥98.5% RP-HPLC:以:0.03%靈酸溶液梯度洗脫 λ:210nm(僅供參考)
含量測定鹽酸扶西汀100513-200401常溫,避光50mg
典帕醇相關(guān)物質(zhì)A標準品60166-98-5 50mg
轉(zhuǎn)錄因子SOX9蛋白抗體品牌天南星Rhizoma Arisaematis Neoshaftoside 新夏佛托苷 61328-41-4 C26H28O14 ≥98%
蔗糖Sucrosq27-20-1200mg
鷓鴣花ichilia connaroides var. connaroides 3,4,5-imetxoxycinnamyl alcohol 3-(3,4,5-氧基本基)- 30273-62-2 C12H16O4 單元素銻溶液成分分析標準物質(zhì)080587
中藥對照藥材藤黃121215-200101TLC法鑒別
Curculigoside仙茅苷 純度:≥98%
抗體的生物素化標記實驗要點:
1. 轉(zhuǎn)錄因子SOX9蛋白抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當則影響標記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件;
3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導致抗體失活;
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等;
5.當游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性;
6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合;
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用;
8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導致高本底。
抗體的鑒定:
1)轉(zhuǎn)錄因子SOX9蛋白抗體品牌 抗體的效價鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。
2)抗體的特異性鑒定:抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3)抗體親和力:是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol??贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。